India’s Anesiva Loses Adlea, Zingo Painkillers From Market
This article was originally published in PharmAsia News
A Phase III trial failed to support India-based Anesiva's Adlea (capsaicin) painkiller at the same time the firm said it would withdraw another painkiller, Zingo (lidocaine), from the U.S. market. The twin moves, according to an analyst, endanger the company's financial future. The trial showed Adlea failed to meet the main goal of the trial, Anesiva said. It withdrew Zingo because of problems with the shelf life of the drug caused by manufacturing difficulties, Anesiva said. The company said it still seeks to form a partnership with another firm on both drugs. Resurrecting Zingo would take at least a year and millions of dollars, the analyst said. (Click here for more
You may also be interested in...
For the first time, the US FDA granted an emergency use authorization to a device that allows for the home collection of saliva for COVID-19 diagnosis. See what Scott Rabuka, senior director of molecular products at DNA Genotek, which developed the test, said about it here.
Deputy CEO Nicolas Hieronimus will take L’Oreal’s helm beginning in May 2021, with Jean-Paul Agon continuing as chairman, the firm announced on 14 October. The Estee Lauder Companies hires PepsiCo’s Gibu Thomas to lead its online business, and Coty appoints its first chief digital officer.
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.